Extended-release tablets to treat schizophrenia approved by KFDA

Published: 2007-12-20 06:57:00

Updated: 2007-12-20 06:57:00

The Korea Food and Drug Administration has approved Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia, a spokesperson at Janssen Korea said.

The once-daily oral medication is specifically designed to deliver paliperidone the active ingredient derived from risperidone through the innovative OROS extended-release technology, demo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.